Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Sangya Agarwal(Amgen (United States)), Carl H. June(University of Pennsylvania), Linhui Chen(Hospital of the University of Pennsylvania), Gabriela Plesa(University of Pennsylvania), Joseph A. Fraietta(University of Pennsylvania), Pranali Ravikumar(Parker Institute for Cancer Immunotherapy), Andrew J. Rech(Parker Institute for Cancer Immunotherapy), Charly R. Good(University of Pennsylvania), Megan M. Davis(California University of Pennsylvania), David L. Porter(Chapman University), M. Ángela Aznar(University of Pennsylvania), Mercy Gohil(University of Pennsylvania), Regina M. Young(University of Pennsylvania), Austin K. Rennels(University of Pennsylvania), January Salas-McKee(University of Pennsylvania), Weimin Kong(Bengbu Medical College), Marco Ruella(Parker Institute for Cancer Immunotherapy), Seok-Jae Albert Hong(University of Pennsylvania), Tong Da(University of Pennsylvania), Shunichiro Kuramitsu(University of Pennsylvania)
Cited by 164
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
|American Journal of Hematology|2019|608
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554